Unravelling Eribulin’s role in metastatic breast cancer: evaluating benefits for both triple negative and non-triple negative patients in real-world scenarios in resource-constrained settings
Eribulin is a viable and safe option for treating heavily pre-treated MBC in real-world settings. The study found comparable efficacy in both TNBC and non-TNBC patients.
Authors
- Shashikant Patne (ORCID: https://orcid.org/0000-0002-1275-7444)
- V. Manikandan
- S. N. Singh (ORCID: https://orcid.org/0000-0001-5707-4148)
- Ankita Kapoor (ORCID: https://orcid.org/0000-0002-6600-6726)
- Prashanth Giridhar (ORCID: https://orcid.org/0000-0002-5354-1463)
- Bipinesh Sansar (ORCID: https://orcid.org/0000-0002-7656-8650)
- Akhil Kapoor (ORCID: https://orcid.org/0000-0001-6006-2631)
- Shreya Shukla (ORCID: https://orcid.org/0000-0002-7815-9252)
- Zachariah Chowdhury (ORCID: https://orcid.org/0000-0002-1766-5012)
- Lincoln Pujari
- Arvind Upadhyay
- Ipsita Dhal
- Bal Krishna Mishra (ORCID: https://orcid.org/0009-0007-1838-7097)
- Anuj Gupta (ORCID: https://orcid.org/0000-0001-7887-3897)
- Yash Jain
- Amit Kumar (ORCID: https://orcid.org/0000-0002-2798-5933)
- Mayank Tripathi
- Neha Singh (ORCID: https://orcid.org/0000-0003-0773-865X)
- Somnath Dey (ORCID: https://orcid.org/0000-0002-3599-8531)
- Pooja Gupta
- Arpita Singh (ORCID: https://orcid.org/0009-0009-3595-983X)
- Kunal Ranjan Vinayak
Institutions
- Homi Bhabha National Institute (IN)
Publication Details
- Journal
- ecancermedicalscience
- Published
- 2024-11-28
- DOI
- https://doi.org/10.3332/ecancer.2024.1804
- Citations
- 2
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.57